Defense Medical Research and Development Program

Department of Defense

Defense Health Program

Congressionally Directed Medical Research Programs

Defense Medical Research and Development Program

 

Applications to the Fiscal Year 2015 (FY15) Joint Program Committee 8/Clinical and Rehabilitative Medicine Research Program (JPC-8/CRMRP) are being solicited for the Defense Health Agency, Research, Development, and Acquisition (DHA RDA) Directorate, by the U.S. Army Medical Research Acquisition Activity (USAMRAA). As directed by the Office of the Assistant Secretary of Defense for Health Affairs [OASD(HA)], the DHA RDA Directorate manages and executes the Defense Health Program (DHP) Research, Development, Test, and Evaluation (RDT&E) appropriation. The US Army Medical Research and Materiel Command (USAMRMC) Congressionally Directed Medical Research Programs (CDMRP) provides Defense Medical Research and Development Program (DMRDP) execution management support for DHP core research program areas, including JPC-8/CRMRP. This Program Announcement and subsequent awards will be managed and executed by CDMRP with strategic oversight from JPC-8/CRMRP.

 

The JPC-8/CRMRP is one of six major DHP core research program areas within the DHP DHA RDA Directorate and is administered with oversight from JPC-8, which consists of Department of Defense (DoD) and non-DoD medical and military technical experts relevant to the program area. The JPC-8/CRMRP focuses on innovations to reconstruct, rehabilitate, and provide definitive care for injured Service members. The ultimate goal is to return the Service members to duty and restore their quality of life. Innovations developed from JPC-8/CRMRP-supported research efforts are expected to improve restorative treatments and rehabilitative care to maximize function for return to duty (RTD) or civilian life. The interest is in medical technologies (drugs, biologics, and devices) and treatment/rehabilitation strategies (methods, guidelines, standards, and information) that will significantly improve the medical care provided to our wounded Service members within the DoD health care system. Implementation of these technologies and strategies should improve the rate of RTD of Service members, the time to RTD, clinical outcome measures, and quality of life, as well as reduce the hospital stay lengths, clinical workload (patient encounters, treatments, etc.), and initial and long-term costs associated with restorative and rehabilitative or acute care.

 

http://cdmrp.army.mil/funding/dmrdp.shtml

 

FY15 Extremity Regeneration Technology/Therapeutic Development Award

Independent extramural investigators at all academic levels (or equivalent)

Supports the translation of promising preclinical findings into products focused on extremity regeneration.

  • The focus is on bone and soft tissue reconstruction, limb and tissue salvage technologies, and regenerative medicine technologies for the treatment of trauma-induced damage.
  • Must specifically address one or both of the FY15 Focus Areas.
  • Research involving human subjects and human anatomical substances is permitted; however, this award mechanism may not be used to conduct clinical trials.

The maximum period of performance is 3 years.

The maximum allowable funding (total costs) for the entire period of performance is $2.1 Million.

 

FY15 Extremity Regeneration Intervention

Independent extramural investigators at all academic levels (or equivalent)

 

  • Supports Phase I, II, or pivotal clinical trial phase development projects focused on extremity regeneration.
  • The focus is on bone and soft tissue reconstruction, limb and tissue salvage technologies, and
  • regenerative medicine technologies for the treatment of trauma-induced damage.
  • Must specifically address one or both of the FY15 Focus Areas.
  • Funding from this award mechanism must support a clinical trial and development-related efforts and
  • may not be used for preclinical research studies.
  • The maximum period of performance is 4 years.
  • The maximum allowable funding (total costs) for the entire period of performance is $4.9 Million.

A pre-application is required and must be submitted through the electronic Biomedical Research Application Portal (eBRAP) at https://eBRAP.org prior to the pre-application deadline. All applications must conform to the final Program Announcements and General Application Instructions that will be available for electronic downloading from the Grants.gov website. The application package containing the required forms for each award mechanism will also be found on Grants.gov. A listing of all CDMRP funding opportunities can be obtained on the Grants.gov website by performing a basic search using CFDA Number 12.420.

 

Applications must be submitted through the federal government's single-entry portal, Grants.gov. Requests for email notification of the Program Announcements release may be sent to Help@eBrap.org. For more information about the NETPR Program or other CDMRP-administered programs, please visit the CDMRP website (http://cdmrp.army.mil).

 

Point of Contact:

CDMRP Help Desk

301-682-5507

Help@eBrap.org